Floatz logo

Therapeutic Asset Ratings

128 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
1.0% ip-001 for
Colon Cancer
Immunophotonics, Inc.P1/2CC (41)
a2b395
Colon Cancer
A2 Biotherapeutics Inc.P1/2CC (41)
a2b543
Colon Cancer
A2 Biotherapeutics Inc.P1/2CC (41)
a2b694
Colon Cancer
A2 Biotherapeutics Inc.P1/2CC (41)
Anti-Kras G12V Mtcr Pbl
Colon Cancer
National Cancer Institute (NCI)P1/2CC (41)
DEXKETOPROFEN
Colon Cancer
Tel Aviv UniversityP1/2CC (41)
gsk4418959
Colon Cancer
GlaxoSmithKlineP1/2CC (41)
ip-001
Colon Cancer
Immunophotonics, Inc.P1/2CC (41)
mdx2001
Colon Cancer
ModeX Therapeutics, An OPKO Health CompanyP1/2CC (41)
METAMIZOLE
Colon Cancer
Tel Aviv UniversityP1/2CC (41)
pds01adc
Colon Cancer
National Cancer Institute (NCI)P1/2CC (41)
Selpercatinib
Colon Cancer
Eli Lilly and CompanyP1/2CC (41)
Solnerstotug
Colon Cancer
Sensei Biotherapeutics, Inc.P1/2CC (41)
Expanded Cb-Nk Cells
Colon Cancer
M.D. Anderson Cancer CenterP1CC (40)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Colon Cancer
National Cancer Institute (NCI)P1/2CC (40)
Certepetide
Colon Cancer
Anup KasiP1/2C (39)
²¹²pb-dotam-grpr1
Colon Cancer
Orano Med Theranostics, SASP1C (37)
Adagrasib
Colon Cancer
M.D. Anderson Cancer CenterP1C (37)
Atx-559
Colon Cancer
Accent TherapeuticsP1C (37)
aur106
Colon Cancer
Aurigene Discovery Technologies LimitedP1C (37)
Brodalumab
Colon Cancer
Brian Henick, MDP1C (37)
Cbi-1214
Colon Cancer
Cartography BiosciencesP1C (37)
Cea Car-T Cells
Colon Cancer
Chongqing Precision Biotech Co., LtdP1C (37)
Hbi-2438
Colon Cancer
HUYABIO International, LLC.P1C (37)
Phn-010
Colon Cancer
Pheon TherapeuticsP1C (37)
Showing 76 to 100 of 128 assets
PreviousPage 4 of 6Next